Improvement of the survival of autologous free-fat transplants in rats using vascular endothelial growth factor 165-transfected bone mesenchymal stem cells.
Chang L., Wang J., Zheng D., Zhang B., Fan Q., Zhu C.
Animal Study, published in Ann Plast Surg (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Ann Plast Surg (2014)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 23429223
- DOI
- 10.1097/SAP.0b013e3182592db1
Abstract (original English)
Autologous free-fat transplantation is limited by fat absorption and fibrosis due to fat necrosis. In this study, we explored the feasibility of using bone mesenchymal stem cells (BMSCs) transfected by vascular endothelial growth factor (VEGF) 165 gene to improve the survival of transplanted fat tissues in a rat model. Bone mesenchymal stem cells with (group A) and without (group B) VEGF165 gene transfection were each mixed with free transplanted fat tissue; then, they were injected subcutaneously at sites on the backs of 36 Sprague-Dawley rats. A control group (group C) was established by using low-glucose Dulbecco modified Eagle medium. The transplants from groups A, B, and C were gathered respectively at 30, 90, and 180 days after transplantation. Transplanted tissue volume and histology were evaluated, and revascularization was quantified by counting the number of capillaries. The survival rate of the A group was significantly higher than that of the B group (P < 0.05), which was significantly higher than that of the C group (P < 0.05). Histologic analysis revealed that both groups A and B had significantly less fat necrosis and fibrosis (P < 0.05). Group A had significantly higher capillary density than the other 2 groups (P < 0.05), and its chloromethyl-1-1'-dioctadecyl-3,3,3', 3'-tetramethylindocarbocyanineperchlorate-labeled BMSCs were also von Willebrand factor positiv
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.